Articles On Micro-X (ASX:MX1)

Highlights ASX posts broad-based gains amid slowing inflation Financials and retail stocks lead positive movement Strategic updates boost emerging sector companies Australia's equity market witnessed a strong trading s...

June CPI comes in at 0.7pc, annual inflation at 2.1pc Broad market strength across six sectors Banks move higher on interest rate cut anticipation   Soft inflation read points to likely rate cut The ASX wasn’t in bad shape by midmorning,...

Let’s check in with what HotCopper users are closely watching at lunchtime. Given that we’re basically on the deadline before companies get a scolding if they don’t report updates, on Wednesday, the ASX announcements list is basically o...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX health up 1.6% over five days as Morgans’ Scott Power says the mood is positive for start of FY26 Wound management house Tetratherix make its ASX debut and breaks an IPO drought for sector ProMedicus surges past $300 for first time fol...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

S&P500 and Nasdaq hit new highs on Big Tech run
 ASX energy leads, but tech holds strong in June
 Defence stocks dominate as DroneShield, Elsight, archTIS surge   Wall Street wrapped up the quarter on a strong note, with both the S&am...

ASX heath sector falls 1.1% over past five days The US FDA approves CSL’s Andembry to prevent attacks of hereditary angioedema Clever Culture systems records its second consecutive quarter of positive cashflow operations Healthcare and li...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

ASX tech rockets 22pc in May Elsight, EROAD, Etherstack and Yojee fly 4DS goes vertical after chip conference   The ASX tech sector didn’t just rally in May, it rocketed. Up more than 22%, it was one of the biggest monthly leaps in recent...

TechnologyOne becomes Canberra’s digital backbone ‘Buy Australian Plan’ aims to make it easier to land a public sector contract ASX tech stocks with signed government deals   The third largest technology stock on the ASX, Technology One (...

ASX heath sector falls 1.3%, trailing ASX 200 up 1.1% as macro picture remains uncertain but ‘little bit better’ Soft-tissue repair company Aroa Biosurgery reconfirms FY25 reported revenue guidance of NZ$81-84 million Medical imaging softe...

Many life science companies stress the virtue of diversity: multiple programs to protect against one of them failing. Diversity can be helpful: after its failed phase III eye disease programs, Opthea would be wishing it had another drug can...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Tech gets its groove back with help from Wall Street and RBA Defence tech darlings like WhiteHawk and Elsight grab the spotlight Harvest Tech goes global, Droneshield fires again   In April 2025, the ASX tech sector finally got its mojo b...

ASX tech sector hit hard by global turmoil Big names on Nasdaq struggle as AI investments raise doubts ASX listed Opyl, Yojee, RocketBoots lead in March   In March, the S&P/ASX 200 Information Technology sector (XIJ) took a big hit, m...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

February chaos hit, Trump’s tariffs rocked markets ASX tech fell hard, WiseTech led the crash EP&T and Envirosuite led gainer, Spacetalk cut losses   February, a month that’s historically been no stranger to chaos, wrapped up with a d...

  Ansell is expanding its manufacturing to be less reliant on China Mayne Pharma pre-announces a strong first-half earnings recovery Alterity Therapeutics raises $40 million on the back of encouraging trial   The maker of personal protect...

  Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

The Nasdaq hit all-time highs in January but DeepSeek is shaking up the AI market ASX tech stocks shows resilience despite global sell-off Pointerra, Hydrix among the best tech stocks last month   The first month of 2025 was one to rememb...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again  Consumer staples led the S&P/ASX 200 sectors in December with tech leading overall in 2024 Niobium and rare earths explorer Aldoro Resources led the...

ASX tech sector up 50pc in 2024, Nasdaq climbs 25pc Archer Materials best tech stock in December Dubber and Brainchip also winners after scoring big contracts   While everyone’s busy drooling over the US mega-tech stocks, there’s a quiet...

It’s been tough going for the ASX on Friday ahead of key US jobs report Bitcoin cooled off after record highs as profit-taking hit APA was up on pipeline news; Iluka slumped on cost blowout   After hitting fresh record highs earlier this...

The ASX200 closed down 0.38% at 8,462 points. Oil steadied after the biggest advance in more than two weeks as OPEC+ made progress towards a deal to delay further the restoration of shuttered supply, and the U.S. imposed more sanctions o...

Aussie shares rebound slightly after GDP data RBA rate cut talk grows amid weak growth Rio Tinto and Sumitomo ink $615m copper deal   Aussie shares were down by about 0.4% on Wednesday, after falling as much as 0.8% earlier in the day. Th...

AI boom lifts ASX tech stocks, XIJ index up 10% in November Appen and Life360 have surged this year, benefiting from global AI hype NoviqTech and Harvest Tech were best performers this month   The artificial intelligence (AI) theme has be...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX hits record high, driven by consumer stocks Zip co-founder steps down, Collins Foods drops Invion doubles after commencing phase I/II trial    The ASX hit a new record on Tuesday, marking its third all-time high in just a week.  At th...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX health stocks fall 2.15% in past five days, while broader market down 1.42%  MedAdvisor drops 30% on latest quarterly result as MicroX and Mach 7 also fall Micro X reports a ‘ho-hum’ results, while AGMs so far remain rather uneventful ...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

Despite the stunning advances in medical science – keyhole and robotic surgery and the like – the seemingly simpler challenges often remain unsolved. One of them is the ability to determine whether a stroke is the most common ischemic form...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

ASX health stocks rise 0.9% in past five days as broader markets lift 1.2%, despite Friday selloff ImpediMed’s latest quarterly result shows sales momentum building for Sozo device  Cold-cathode X-ray machine developer MicroX makes progres...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Micro-X embarking on ‘biggest advancement in X-ray since its invention’ in 1895 Its X-ray technology is smaller, lighter, more portable and faster than ever before Building its capability not just in medical sector but also security and de...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX tech sector falls 3.87% in April, but still outpaces broader markets YTD with a 19.55% rise Rich-lister Richard White increases his stake in ASX-listed music company Vinyl Group in April Video tech player Linius Technologies rises 33%...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

By Tim Boreham, Editor ASX code: ((HYD)) Market cap: $4.3m Shares on issue: 254,218,847 Financials (December half 2023): revenue $5.97m (down -17.5%), loss of $3.82m (-$1.96m deficit previously), cash of $847,277 (down -73.5%)* * After bala...